Literature DB >> 22706203

The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.

Göran Jönsson1, Johan Staaf, Johan Vallon-Christersson, Markus Ringnér, Sofia K Gruvberger-Saal, Lao H Saal, Karolina Holm, Cecilia Hegardt, Adalgeir Arason, Rainer Fagerholm, Camilla Persson, Dorthe Grabau, Ellinor Johnsson, Kristina Lövgren, Linda Magnusson, Päivi Heikkilä, Bjarni A Agnarsson, Oskar T Johannsson, Per Malmström, Mårten Fernö, Håkan Olsson, Niklas Loman, Heli Nevanlinna, Rosa B Barkardottir, Åke Borg.   

Abstract

Breast tumors from BRCA1 germ line mutation carriers typically exhibit features of the basal-like molecular subtype. However, the specific genes recurrently mutated as a consequence of BRCA1 dysfunction have not been fully elucidated. In this study, we used gene expression profiling to molecularly subtype 577 breast tumors, including 73 breast tumors from BRCA1/2 mutation carriers. Focusing on the RB1 locus, we analyzed 33 BRCA1-mutated, 36 BRCA2-mutated, and 48 non-BRCA1/2-mutated breast tumors using a custom-designed high-density oligomicroarray covering the RB1 gene. We found a strong association between the basal-like subtype and BRCA1-mutated breast tumors and the luminal B subtype and BRCA2-mutated breast tumors. RB1 was identified as a major target for genomic disruption in tumors arising in BRCA1 mutation carriers and in sporadic tumors with BRCA1 promoter methylation but rarely in other breast cancers. Homozygous deletions, intragenic breaks, or microdeletions were found in 33% of BRCA1-mutant tumors, 36% of BRCA1 promoter-methylated basal-like tumors, 13% of non-BRCA1-deficient basal-like tumors, and 3% of BRCA2-mutated tumors. In conclusion, RB1 was frequently inactivated by gross gene disruption in BRCA1 hereditary breast cancer and BRCA1-methylated sporadic basal-like breast cancer but rarely in BRCA2 hereditary breast cancer and non-BRCA1-deficient sporadic breast cancers. Together, our findings show the existence of genetic heterogeneity within the basal-like breast cancer subtype that is based upon BRCA1 status. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22706203     DOI: 10.1158/0008-5472.CAN-12-0097

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

Review 1.  Genotype/Phenotype correlations in patients with hereditary breast cancer.

Authors:  Maike Wittersheim; Reinhard Büttner; Birgid Markiefka
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

2.  Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.

Authors:  Karolina Holm; Dorthe Grabau; Kristina Lövgren; Steina Aradottir; Sofia Gruvberger-Saal; Jillian Howlin; Lao H Saal; Stephen P Ethier; Pär-Ola Bendahl; Olle Stål; Per Malmström; Mårten Fernö; Lisa Rydén; Cecilia Hegardt; Åke Borg; Markus Ringnér
Journal:  Mol Oncol       Date:  2012-06-20       Impact factor: 6.603

Review 3.  The complex genetic landscape of familial breast cancer.

Authors:  Lorenzo Melchor; Javier Benítez
Journal:  Hum Genet       Date:  2013-04-05       Impact factor: 4.132

4.  Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer.

Authors:  Michael E Feigin; S Dipikaa Akshinthala; Kiyomi Araki; Avi Z Rosenberg; Lakshmi B Muthuswamy; Bernard Martin; Brian D Lehmann; Hal K Berman; Jennifer A Pietenpol; Robert D Cardiff; Senthil K Muthuswamy
Journal:  Cancer Res       Date:  2014-03-24       Impact factor: 12.701

Review 5.  Hereditary breast and ovarian cancer: new genes in confined pathways.

Authors:  Finn Cilius Nielsen; Thomas van Overeem Hansen; Claus Storgaard Sørensen
Journal:  Nat Rev Cancer       Date:  2016-08-12       Impact factor: 60.716

6.  Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence.

Authors:  Maja Sedic; Adam Skibinski; Nelson Brown; Mercedes Gallardo; Peter Mulligan; Paula Martinez; Patricia J Keller; Eugene Glover; Andrea L Richardson; Janet Cowan; Amanda E Toland; Krithika Ravichandran; Harold Riethman; Stephen P Naber; Anders M Näär; Maria A Blasco; Philip W Hinds; Charlotte Kuperwasser
Journal:  Nat Commun       Date:  2015-06-24       Impact factor: 14.919

7.  High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer.

Authors:  Inga Reynisdottir; Adalgeir Arason; Berglind O Einarsdottir; Haukur Gunnarsson; Johan Staaf; Johan Vallon-Christersson; Goran Jonsson; Markus Ringnér; Bjarni A Agnarsson; Kristrun Olafsdottir; Rainer Fagerholm; Thorbjorg Einarsdottir; Gudrun Johannesdottir; Oskar Thor Johannsson; Heli Nevanlinna; Ake Borg; Rosa Bjork Barkardottir
Journal:  Cancer Med       Date:  2013-05-22       Impact factor: 4.452

8.  BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival.

Authors:  Chiara Gorrini; Pegah S Baniasadi; Isaac S Harris; Jennifer Silvester; Satoshi Inoue; Bryan Snow; Purna A Joshi; Andrew Wakeham; Sam D Molyneux; Bernard Martin; Peter Bouwman; David W Cescon; Andrew J Elia; Zoe Winterton-Perks; Jennifer Cruickshank; Dirk Brenner; Alan Tseng; Melinda Musgrave; Hal K Berman; Rama Khokha; Jos Jonkers; Tak W Mak; Mona L Gauthier
Journal:  J Exp Med       Date:  2013-07-15       Impact factor: 14.307

9.  Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.

Authors:  Martin J Larsen; Torben A Kruse; Qihua Tan; Anne-Vibeke Lænkholm; Martin Bak; Anne E Lykkesfeldt; Kristina P Sørensen; Thomas V O Hansen; Bent Ejlertsen; Anne-Marie Gerdes; Mads Thomassen
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

10.  RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families.

Authors:  Martin J Larsen; Mads Thomassen; Qihua Tan; Anne-Vibeke Lænkholm; Martin Bak; Kristina P Sørensen; Mette Klarskov Andersen; Torben A Kruse; Anne-Marie Gerdes
Journal:  BMC Med Genomics       Date:  2014-01-31       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.